Previous Article | Next Article 
Clinical and Diagnostic Laboratory Immunology, January 2000, p. 91-95, Vol. 7, No. 1
1071-412X/0/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
Molecular Cloning and Nucleotide Sequence Analysis
of a Novel Human Papillomavirus (Type 82) Associated with Vaginal
Intraepithelial Neoplasia
Nao
Kino,1
Tetsutaro
Sata,1
Yuko
Sato,1
Motoyasu
Sugase,2 and
Toshihiko
Matsukura3,*
Department of Pathology and Laboratory of
Pathology, AIDS Research Center,1 and
Laboratory of Tumor Viruses, Department of Virology
II,3 National Institute of Infectious
Diseases, Tokyo, and Department of Obstetrics and
Gynecology, Nagano Red Cross Hospital,
Nagano,2 Japan
Received 26 July 1999/Returned for modification 6 October
1999/Accepted 4 November 1999
 |
ABSTRACT |
The genome of a novel human papillomavirus (HPV-82) was cloned from
a vaginal intraepithelial neoplasia grade I. In our series of 291 biopsy specimens, HPV-82 was identified in one case each of cervical
intraepithelial neoplasia grade II and grade III by blot hybridization.
The histological localization of HPV-82 DNA in the three lesions was
confirmed by in situ hybridization. The results indicated that HPV-82
is an etiologic agent for vaginal and cervical intraepithelial
neoplasia. By nucleotide sequence similarity of L1 open reading frame
(ORF), HPV-82 was closely related to HPV-26, -51, and -69. To know the
precise relationship between the HPVs, we determined the complete
sequence of HPV-82, as well as that of HPV-69. Sequencing revealed that
the four HPVs had no initiation codon in the E5 ORF and had extensive
nucleotide sequence similarities in all ORFs. In addition, they
exhibited unique frame position patterns for ORFs, different from those of the other genital HPVs.
 |
INTRODUCTION |
Human papillomavirus (HPV) has a
genome of closed-circular double-stranded DNA and HPV type 1 (HPV-1),
HPV-2, and HPV-4 were first molecularly cloned in 1980 (6).
During the past 20 years, 79 distinct HPVs have been cloned
(4), of which 39 HPVs are labeled as genital HPV, having the
potential to induce genital tumors (17). Genital HPVs are
pathologically classified into two groups, high-risk types associated
with malignant tumors and low-risk types associated with benign tumors.
HPV-16 and -18 were first classified as high-risk types in 1986 (21), and then eight other HPVs (HPV-31, -33, -35, -45, -51, -52, -56, and -58) were added in 1992 (9). However, all 39 genital HPVs were not yet rationally classified in these groups, and
HPVs designated as high-risk types were different from study to study
(5, 7, 8, 15). For example, Jacobs et al. designated 14 high-risk types: HPV-16, -18, -31, -33, -35, -39, -45, -51, -52, -56, -58, -59, -66, and -68 (8). On the other hand, Gravitt et
al. designated 15 high-risk types: HPV-16, -18, -26, -31, -33, -35, -39, -45, -51, -52, -55, -56, -58, -59, and -68 (5).
Surprisingly enough, HPV-66, classified as a high-risk type in the
former study, was considered a low-risk type in the latter. It was not
known how each HPV was classified in these studies. We speculated that
any HPV detected in invasive cervical carcinoma (ICC) might be
categorized as a high-risk type (1). However, the mere
detection of viral fragment DNA in ICC is not sufficient to establish
the causality of ICC. To be considered an etiologic agent for ICC, any
HPV DNA should be histopathologically demonstrated in at least a single case of ICC by in situ hybridization (18).
In the present study, we report the cloning and nucleotide sequencing
of a novel genital HPV, partial nucleotide sequences of which have been
detected in ICC by PCR. In addition, we examined the histopathologic
localization of the viral DNA in different genital lesions.
 |
MATERIALS AND METHODS |
Histopathology, immunohistochemistry, and in situ
hybridization.
The biopsy specimens were divided into two parts,
one of which was fixed in 10% buffered formalin for routine
histopathology. In addition, paraffin sections were tested by
immunohistochemistry for the presence of viral capsid antigen with an
anti-HPV capsid antibody, K1H8 (Dako Corp., Carpinteria, Calif.).
Briefly, sections were incubated with the antibody at 4°C overnight
and sequentially reacted with biotinylated anti-mouse immunoglobulin G
antibody and the avidin-biotin complex solution (Vector Laboratories,
Burlingame, Calif.). To examine the histological localization of HPV
DNA in the lesion, paraffin sections were applied to in situ
hybridization as reported previously (19). Briefly, after
proteinase K treatment, the sections were fixed in 4%
paraformaldehyde-0.1 M phosphate-buffered saline (pH 7.4) and
dehydrated. The sections were then mounted with 20 µl of
hybridization buffer containing 10 ng of biotinylated HPV DNA probe and
denatured at 95°C for 5 min. After hybridization at 42°C for
14 h, the sections were washed three times in 0.2× SSC (1× SSC
is 0.15 M NaCl and 0.015 M sodium citrate) at 50°C and blocked with
Blockace (Snow Brand, Tokyo, Japan) at room temperature. Finally, the
biotinylated viral DNA was visualized by incubation with a
streptavidin-alkaline phosphatase complex, followed by nitroblue
tetrazolium-5-bromo-4-chloro-3-indolylphosphate treatment (Dako in
situ detection kit; Dako, Kyoto, Japan). The sections were
counterstained with 2% methyl green.
Molecular cloning and nucleotide sequencing of HPV genome.
The other part of the biopsy specimens was used for HPV analysis by
blot hybridization (12). Briefly, total DNA from biopsy specimens was digested with an appropriate restriction enzyme and
electrophoresed in a 1% agarose gel, with 40 mM Tris-acetate-2 mM
EDTA (pH 8.0) as running buffer. After transfer to a nitrocellulose filter, DNA was hybridized with 32P-labeled HPV-58 DNA
probe at a Tm
40°C in 5× SSC-50 mM HEPES buffer (pH 7.0)-0.02% each polyvinylpyrrolidone and Ficoll-20% formamide at 42°C. The filter was then washed at a
Tm
40°C and exposed to X-ray film with
intensifying screens at
80°C.
Molecular cloning of the HPV genome was done as reported previously
with some modifications (11). Total DNA was digested with a
single-cut enzyme and electrophoresed in a 1% agarose gel. The 7- to
8-kb fragment was removed and purified by electroelution. One hundred
nanograms of the DNA was ligated with 50 ng of plasmid DNA and used to
transform Escherichia coli JM109. From the resultant colonies, positive clones were selected by hybridization analysis with
an HPV-58 probe. HPV DNA was sequenced by the primer walking method
(3) and the dye terminator cycle sequencing method. For the
sequence comparison, the complete nucleotide sequences of HPV-26
(X744272) and HPV-51 (M62877) were obtained from the databases and
analyzed with DNASIS software (Hitachi Software Engineering, Tokyo, Japan).
Nucleotide sequence accession numbers.
The nucleotide
sequences established in the present study have been submitted to the
DDBJ, EMBL, and GenBank nucleotide sequence databases under the
accession no. AB027020 for HPV-69 and AB027021 for HPV-82.
 |
RESULTS |
Molecular cloning of HPV-82 DNA and in situ hybridization.
Under colposcopy, a lesion showing sharply demarcated white epithelium
was biopsied (Fig. 1a). It was
histopathologically diagnosed as vaginal intraepithelial neoplasia
(VAIN) grade I (Fig. 1b), and HPV capsid antigen was detected within
the nuclei of the superficial koilocytotic cells by
immunohistochemistry (Fig. 1c). Subsequently, we looked for HPV DNA in
the lesion by blot hybridization with 32P-labeled HPV-58
DNA probe at a Tm
40°C. As shown in Fig.
2, the lesion harbored a possible HPV DNA
with characteristic PstI, BanI, and
MspI cleavage patterns, different from those of any known
HPVs. In addition, the positive bands were detected at the positions of
forms I, II, and III of a circular double-stranded DNA of approximately
8 kb (FI, FII, and FIII in lanes BamHI, EcoRI, and EcoRV, respectively), although the intensity of form I
DNA was extremely low. Furthermore, it was assumed that forms I and II
were converted to form III with XbaI digestion. Accordingly, we cloned the DNA by using a plasmid vector, pBluescript KS
(Stratagene, La Jolla, Calif.), and a possible single-cut restriction
enzyme, XbaI. We then determined partial sequences of the
cloned DNA, corresponding to the L1 open reading frame (ORF) of HPV,
which showed less than 90% nucleotide sequence identity to L1
sequences of any known HPVs at that time. The clone was named HPV-82.
The VAIN lesion was revealed to harbor more than 3,000 viral copies per
cell by blot hybridization with the cloned HPV-82 DNA as probe. Furthermore, we examined the presence of other genital HPVs in the
lesion by blot hybridization with different HPV probes and found no
other HPV. Consequently, the histological localization of HPV-82 DNA in
the lesion was examined by using paraffin sections and biotinylated
HPV-82 DNA probe. As can be seen in Fig. 1d, viral DNA was abundantly
found in the nuclei of superficial cells of the lesion as was the viral
capsid antigen; moreover, it was disclosed in deeper intermediate cells
than was the antigen. Together with the blot hybridization analysis, it
was assumed that the whole genome of HPV-82 might replicate in most
cells of the lesion and produce progeny virions in some
superficial cells. In our series of 220 cervical
intraepithelial neoplasias (CINs), HPV-82 was identified in one case
each of CIN II and CIN III by blot hybridization, and the viral DNA was
demonstrated in the lesions by in situ hybridization (data not shown).
The results indicated that HPV-82 has a potential to induce VAIN and
CIN.

View larger version (116K):
[in this window]
[in a new window]
|
FIG. 1.
VAIN. (a) Colposcopic appearance of VAIN lesion from
which HPV-82 was cloned. (b) Paraffin section of the lesion stained
with hematoxylin and eosin. (c) Immunohistochemistry with anti-HPV
capsid antibody. (d) In situ hybridization with biotinylated HPV-82 DNA
probe. Scale bars = 500 µm.
|
|

View larger version (44K):
[in this window]
[in a new window]
|
FIG. 2.
Blot hybridization analysis of HPV sequences in a VAIN
lesion. Total DNA from biopsy specimens was digested with the
restriction enzymes indicated above the lanes and electrophoresed in a
1% agarose gel. After transfer to a nitrocellulose filter, DNA was
hybridized with 32P-labeled HPV-58 DNA probe at a
Tm 40°C. DNA markers are indicated in
kilobases.
|
|
Nucleotide sequences of HPV-69 and HPV-82.
By L1 sequence
analysis, HPV-82 was closely related to HPV-26, -51, and -69. In
addition, it was noted that the MM4 sequence in the databases was
nearly identical to a part of the L1 sequence of HPV-82 (442 of 455 bp
[97%]). To know the precise relationship among the four HPVs, we
determined the entire nucleotide sequence of HPV-82, as well as that of
HPV-69, cloned originally in our laboratory (17). HPV-69
consists of 7,700 nucleotides with a 38.8% GC content, while HPV-82
consists of 7,871 nucleotides with a 40.2% GC content. It was notable
that restriction enzyme cleavage patterns deduced from the sequences
corresponded well to the patterns detected by blot hybridization. For
example, PstI fragments of the HPV-82 sequence were 3,892, 3,621, and 358 bp, which were consistent with the fragment sizes seen
in lane PstI of Fig. 2. It was assumed that the whole
genomes of HPV-69 and HPV-82 were cloned without deletion. Both HPVs
have all major ORFs on one strand, characteristic of papillomavirus.
The positions of ORFs and the numbers of amino acids of their putative
encoded proteins are summarized in Table
1. We then compared the sequences with those of HPV-26 (7,855 nucleotides; 38.6%GC) and HPV-51 (7,808 nucleotides; 39.1% GC). As shown in Table 1, the four HPVs had ORFs
with nearly identical sizes and no initiation codon in the E5 ORF,
although HPV-26 and -69 also had no initiation codon in the E4 ORF. By
fixing the position of the E6 ORF at the first of three reading frames,
it was revealed that the frame position patterns for ORFs of these HPVs
were quite different from those of the other genital HPVs. For example,
the E7 ORF of these four HPVs was positioned at the first or second
frame, whereas the E7 ORF of 31 other genital HPVs, except HPV-52, -59, and -73, was in the third frame (data not shown). The percent
similarities of nucleotide and amino acid sequences of each ORF among
HPV-26, -51, -69, and -82 are summarized in Table
2. The HPVs had high similarities in all
ORFs. To be precise, HPV-26 and -69 and HPV-51 and -82 were much more
closely related to each other. Each set of two HPVs exhibited similar
features, such as GC content, frame position patterns for ORFs, and
ORFs without initiation codons.
 |
DISCUSSION |
By phylogenetic analysis of partial L1 sequences of
papillomavirus, HPV-82, as MM4, had been classified in group A5 of
supergroup A, together with HPV-26, -51, and -69 (2). As
clustered in the group, the four HPVs had extensive nucleotide and
amino acid sequence similarities for all the other ORFs (Table 2),
suggesting that the HPVs might have similar biological activities in
inducing genital lesions. Owing to analysis of whole genomes, it was
revealed that this group has no initiation codon in E5 and/or E4 ORFs
and exhibits distinct frame position patterns for ORFs (Table 1). Although there was no explanation of the significance of the features, they might implicate some biological and functional effects.
This group might be distinct among HPVs, having tropism both for the
skin and for the genital mucosa. HPV-26 was originally cloned from
papillomas on the skin (14) and found in cervicovaginal lavage specimens (7). On the other hand, HPV-51 was cloned from a cervical condyloma (13) and was detected in basal
cell carcinomas of the skin (16). In addition, HPV-69 and
HPV-82, cloned from VAIN lesions, were found in a dysplastic wart or in squamous cell carcinomas of the skin (16; T. Matsukura, unpublished data).
HPV-82, as W13B/MM4, was first found in exfoliated cells of women with
normal cytology by sequencing of PCR amplimer (10). Table
3 shows the distribution of HPV-82, as
well as of HPV-26, -51, and -69, in different geographic areas. In
study 1, we analyzed biopsy specimens by blot hybridization (12,
17). In contrast, smear and biopsy specimens were examined by PCR
in study 2 (20) and study 3 (1), respectively. It
was clear that HPV-82 is widespread. Since we confirmed the presence of
HPV-51 and -69 DNA in our cases by in situ hybridization, this group
should be etiologic agents for CIN or VAIN. However, we wondered
whether the group might be responsible for inducing ICC (5,
7). To establish the causality for ICC, it would be essential to
histopathologically demonstrate the viral DNA in ICC, as mentioned
above.
In conclusion, we have cloned HPV-82, closely related to HPV-26, -51, and -69, and determined the complete nucleotide sequences of HPV-69 and
-82. The four HPVs might be a distinct group among genital HPVs,
exhibiting unique frame position patterns for ORFs.
 |
ACKNOWLEDGMENTS |
We gratefully acknowledge the help of H. Delius and E.-M. de
Villiers in the identification of new HPV types.
This research was supported by grants from the Ministry of Health and
Welfare for 2nd-Term Comprehensive 10-Year Strategy for Cancer Control, Japan.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Laboratory of
Tumor Viruses, Department of Virology II, National Institute of
Infectious Diseases, 1-23-1 Toyama, Shinjuku, Tokyo 162-8640, Japan.
Phone: 81 3 5285 1111. Fax: 81 3 5285 1161. E-mail: toshi{at}nih.go.jp.
 |
REFERENCES |
| 1.
|
Bosh, F. X.,
M. M. Manos,
N. Munoz,
M. Sherman,
A. M. Jansen,
J. Peto,
M. H. Schiffman,
V. Moreno,
R. Kurman, and K. V. Shah.
1995.
Prevalence of human papillomavirus in cervical cancer: a worldwide perspective.
J. Natl. Cancer Inst.
87:796-802[Abstract/Free Full Text].
|
| 2.
|
Chan, S.-Y.,
H. Delius,
A. L. Halpern, and H.-U. Bernard.
1995.
Analysis of genomic sequences of 95 papillomavirus types: uniting typing, phylogeny, and taxonomy.
J. Virol.
69:3074-3083[Abstract].
|
| 3.
|
Delius, H., and B. Hofmann.
1994.
Primer-directed sequencing of human papillomavirus types.
Curr. Top. Microbiol. Immunol.
186:13-31[Medline].
|
| 4.
|
Delius, H.,
B. Saegling,
K. Bergmann,
V. Shamanin, and E.-M. de Villiers.
1998.
The genomes of three of four novel HPV types, defined by differences of their L1 genes, show high conservation of the E7 gene and the URR.
Virology
240:359-365[CrossRef][Medline].
|
| 5.
|
Gravitt, P. E.,
C. L. Peyton,
R. J. Apple, and C. M. Wheeler.
1998.
Genotyping of 27 human papillomavirus types by using L1 consensus PCR products by a single-hybridization, reverse line blot detection method.
J. Clin. Microbiol.
36:3020-3027[Abstract/Free Full Text].
|
| 6.
|
Heilman, C. A.,
M.-F. Law,
M. A. Israel, and P. M. Howley.
1980.
Cloning of human papilloma virus genomic DNAs and analysis of homologous polynucleotide sequences.
J. Virol.
36:395-407[Abstract/Free Full Text].
|
| 7.
|
Ho, G. Y. F.,
R. Bierman,
L. Beardsley,
C. J. Chang, and R. D. Burk.
1998.
Natural history of cervicovaginal papillomavirus infection in young women.
N. Engl. J. Med.
338:423-428[Abstract/Free Full Text].
|
| 8.
|
Jacobs, M. V.,
P. J. F. Snijders,
A. J. C. van den Brule,
T. J. M. Helmerhorst,
C. J. L. M. Meijer, and J. M. M. Walboomers.
1997.
A general primer GP5+/GP6+-mediated PCR-enzyme immunoassay method for rapid detection of 14 high-risk and 6 low-risk human papillomavirus genotypes in cervical scrapings.
J. Clin. Microbiol.
35:791-795[Abstract].
|
| 9.
|
Lorincz, A. T.,
R. Reid,
A. B. Jenson,
M. D. Greenberg,
W. Lancaster, and R. J. Kurman.
1992.
Human papillomavirus infection of the cervix: relative risk associations of 15 common anogenital types.
Obstet. Gynecol.
79:328-337[Medline].
|
| 10.
|
Manos, M. M.,
J. Waldman,
T. Y. Zhang,
C. E. Greer,
G. Eichinger,
M. H. Schiffman, and C. M. Wheeler.
1994.
Epidemiology and partial nucleotide sequence of four novel genital human papillomaviruses.
J. Infect. Dis.
170:1096-1099[Medline].
|
| 11.
|
Matsukura, T., and M. Sugase.
1990.
Molecular cloning of a novel human papillomavirus (type 58) from an invasive cervical carcinoma.
Virology
177:833-836[CrossRef][Medline].
|
| 12.
|
Matsukura, T., and M. Sugase.
1995.
Identification of genital human papillomaviruses in cervical biopsy specimens: segregation of specific virus types in specific clinicopathologic lesions.
Int. J. Cancer
61:13-22[Medline].
|
| 13.
|
Nuovo, G. J.,
C. P. Crum,
E.-M. de Villiers,
R. U. Levine, and S. J. Silverstein.
1988.
Isolation of a novel human papillomavirus (type 51) from a cervical condyloma.
J. Virol.
62:1452-1455[Abstract/Free Full Text].
|
| 14.
|
Ostrow, R. S.,
K. R. Zachow,
O. Thompson, and A. J. Faras.
1984.
Molecular cloning and characterization of a unique type of human papillomavirus from an immune deficient patient.
J. Investig. Dermatol.
82:362-366[CrossRef][Medline].
|
| 15.
|
Qu, W.,
G. Jiang,
Y. Cruz,
C. J. Chang,
G. Y. Ho,
R. S. Klein, and R. D. Burk.
1997.
PCR detection of human papillomavirus: comparison between MY09/MY11 and GP5+/GP6+ primer systems.
J. Clin. Microbiol.
35:1304-1310[Abstract].
|
| 16.
|
Shamanin, V.,
H. zur Hausen,
D. Lavergne,
C. M. Proby,
I. M. Leigh,
C. Neumann,
H. Hamm,
M. Goss,
U.-F. Haustein,
E. G. Jung,
G. Plewig,
H. Wolff, and E.-M. de Villiers.
1996.
Human papillomavirus infections in nonmelanoma skin cancers from renal transplant recipients and nonimmunosuppressed patients.
J. Natl. Cancer Inst.
88:802-811.
|
| 17.
|
Sugase, M., and T. Matsukura.
1997.
Distinct manifestations of human papillomaviruses in the vagina.
Int. J. Cancer
72:412-415[CrossRef][Medline].
|
| 18.
|
Tawheed, A. R.,
S. Beaudenon,
M. Favre, and G. Orth.
1991.
Characterization of human papillomavirus type 66 from an invasive carcinoma of the uterine cervix.
J. Clin. Microbiol.
29:2656-2660[Abstract/Free Full Text].
|
| 19.
|
Terai, M.,
M. Takagi,
T. Matsukura, and T. Sata.
1999.
Oral wart associated with human papillomavirus type 2.
J. Oral Pathol. Med.
28:137-140[Medline].
|
| 20.
|
Wheeler, C.
1996.
Human papillomavirus type-specific prevalence, p. 112-124.
In
G. Myers, H. Delius, J. Icenogel, H.-U. Bernard, C. Baker, A. Halpern, and C. Wheeler (ed.), Human papillomavirus 1996, vol. III. Los Alamos National Laboratory, Los Alamos, N.Mex.
|
| 21.
|
zur Hausen, H.
1995.
Are human papillomavirus infections not necessary or sufficient causal factors for invasive cancer of the cervix?
Int. J. Cancer
63:315-316[Medline].
|
Clinical and Diagnostic Laboratory Immunology, January 2000, p. 91-95, Vol. 7, No. 1
1071-412X/0/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Menzo, S., Monachetti, A., Trozzi, C., Ciavattini, A., Carloni, G., Varaldo, P. E., Clementi, M.
(2001). Identification of Six Putative Novel Human Papillomaviruses (HPV) and Characterization of Candidate HPV Type 87. J. Virol.
75: 11913-11919
[Abstract]
[Full Text]